Who should decide if a drug is worth the cost?

With our new President in office, the debate continues about America's seemingly unlimited spending on prescription medications and the best ways to control healthcare costs. Scott Gottlieb wrote an op-ed in the Wall Street Journal opposing the strategies he sees President Obama and the new administration considering to solve the problem.  Report.

 

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.